アルファエミッターの2030年までの市場予測：タイプ、ソース、用途、エンドユーザー、地域別の世界分析

Stratistics MRCによると、アルファエミッターの世界市場は2023年に6億7,840万米ドルを占め、予測期間中にCAGR 13.4％で成長し、2030年には16億3,600万米ドルに達する見込みです。

アルファ放出核種とは、アルファ崩壊を起こし、その過程でアルファ粒子を放出する放射性物質または同位体を指します。アルファ粒子は2個の陽子と2個の中性子からなり、実質的にヘリウム4の原子核に相当します。このタイプの放射性崩壊の特徴は、原子核からアルファ粒子が放出され、その結果、元の元素が原子番号の低い新しい元素に変化することです。アルファエミッター核種の利用は、医療、産業、研究などさまざまなセグメントで応用されています。

国際がん研究機関（IARC）によると、2040年までに、主に人口増加と高齢化により、世界のがん罹患者数は2,750万人、がん死亡者数は1,630万人に増加すると予測されています。

アルファ粒子治療の認知度上昇

市場は、特にアルファ粒子治療の認知度の高まりによって、認知度の急上昇を経験しています。医学の進歩に伴い、標的を絞ったがん治療におけるアルファ粒子による治療の可能性に対する理解が高まっています。アルファ粒子療法は、高度に局所化された強力な放射線を照射することで、周囲の健康な組織へのダメージを最小限に抑えながら特定の種類のがんを治療する効果を高めています。意識の高まりは、アルファエミッター核種に対する需要を促進し、このセグメントにおけるさらなる技術革新と進歩を促すと思われます。

放射性医薬品の短い半減期

放射性医薬品の半減期が短いことが課題となっており、医療や産業への効果的な応用が制限されています。急速な減衰は、治療や実験の機会を減少させ、効率的なロジスティクスと迅速な配備を必要とします。この制約がアルファエミッター核種の普及に影響を与える可能性があり、特に、望ましい結果を得るためには長時間の放射能が不可欠であり、計画や実施において減衰率を注意深く考慮する必要があるシナリオではなおさらです。

核医学の進歩

核医学市場における最近の進歩は、革新的な標的アルファ粒子治療に焦点を当てています。アルファエミッター核種は、腫瘍細胞に局所的に放射線を照射し、周囲の健康な組織への損傷を最小限に抑えることで、がん治療において高い精度を示します。こうした開発により治療介入の有効性と安全性が向上し、個別化医療が大きく進展し、特定のがん患者の転帰が改善されます。

多額の設備投資の必要性

アルファエミッター技術は複雑かつ専門的であるため、市場は多額の設備投資を必要とします。安全な生産施設の設置、厳格な規制基準の遵守の確保、安全な応用のための高度な研究開発への投資には、多額の資金が必要となります。さらに、広範な安全対策と管理された環境が必要なため、全体として必要資本が高くなり、潜在的な市場参入企業にとっては参入障壁となります。

COVID-19の影響：

COVID-19の大流行は、サプライチェーンの混乱、研究開発プロジェクトの遅延、規制プロセスへの影響によって市場に影響を与えました。パンデミックの間に医療への関心が高まったことは、医療用途に使用されるアルファエミッター装置の需要にプラスにもマイナスにも影響しました。がん治療のニーズが高まる一方で、物流上の課題やリソースの優先順位付けが障害となっています。世界の健康危機がもたらしたダイナミックな状況により、市場全体が変動を経験しています。

ビスマスセグメントが予測期間中最大となる見込み

ビスマスセグメントは予測期間中最大となる見込みです。ビスマスは、ある種のがんを治療するための標的アルファ粒子放射線療法に利用されています。半減期が短く、高エネルギーのアルファ粒子を供給できることから、正確で効果的ながん治療に利用されています。革新的な医療療法への注目の高まりが、ビスマス-213の需要拡大に寄与しており、医療セグメントにおけるアルファエミッター核種応用の進展におけるビスマス-213の重要性を裏付けています。

予測期間中、卵巣がんセグメントのCAGRが最も高くなると予想される

卵巣がんセグメントは、予測期間中に最も高いCAGRが見込まれます。この標的アプローチにより、周囲の健康な組織へのダメージが最小限に抑えられます。しかし、規制当局の承認、安全性への配慮、さらなる臨床エビデンスの必要性などが、普及に影響を及ぼす可能性があります。卵巣がん治療と研究の進化は、この課題への取り組みにおけるアルファエミッター装置の役割に影響を与えると思われます。

最大のシェアを占める地域

北米は、医療、特にがん治療への応用が増加しているため、予測期間中最大の市場シェアを占めると予測されます。原子力への投資と研究開発の活発化が市場拡大に寄与しています。国民の認識と規制遵守は、依然として同地域のアルファエミッター装置の成長に影響を与える極めて重要な要因です。

CAGRが最も高い地域：

アジア太平洋は、医療、研究、原子力発電における用途の増加により、予測期間中最も高いCAGRを維持すると予測されます。がん罹患率の増加が、標的アルファ粒子放射線治療の需要を促進しています。同地域の医療部門の拡大と研究活動が同地域の可能性に寄与していますが、進行中の市場開拓と安全プロトコルの遵守が、同地域の市場の軌道を形成する上で極めて重要な役割を果たすと考えられます。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 研究ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のアルファエミッター市場：タイプ別

• イントロダクション
• 鉛
• アスタチン
• ビスマス
• ラジウム
• アクチニウム
• その他

第6章 世界のアルファエミッター市場：ソース別

• イントロダクション
• 人工
• 天然

第7章 世界のアルファエミッター市場：用途別

• イントロダクション
• 前立腺がん
• 神経内分泌腫瘍
• 骨転移
• 卵巣がん
• その他

第8章 世界のアルファエミッター市場：エンドユーザー別

• イントロダクション
• 専門クリニック
• 診断センター
• 病院
• その他

第9章 世界のアルファエミッター市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第10章 主要発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Orano Group
• Alpha Tau Medical Ltd
• Actinium Pharmaceutical Inc.
• Novartis International AG
• Bayer AG
• NorthStar Medical Radioisotopes
• Fusion Pharmaceuticals Inc.
• Telix Pharmaceuticals Ltd
• Eckert & Ziegler
• RadioMedix
• Curium Pharma
• Isotopen Technologien Munchen AG（ITM）
• Nordion Inc.

List of Tables

• Table 1 Global Alpha Emitter Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 4 Global Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 5 Global Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 6 Global Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 7 Global Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 8 Global Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 9 Global Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 10 Global Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 11 Global Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 12 Global Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 13 Global Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 14 Global Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 15 Global Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 16 Global Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 17 Global Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 18 Global Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 19 Global Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 20 Global Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 21 Global Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 22 Global Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 23 North America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
• Table 24 North America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 25 North America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 26 North America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 27 North America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 28 North America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 29 North America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 30 North America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 31 North America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 32 North America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 33 North America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 34 North America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 35 North America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 36 North America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 37 North America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 38 North America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 39 North America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 40 North America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 41 North America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 42 North America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 43 North America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 44 North America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 45 Europe Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
• Table 46 Europe Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 47 Europe Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 48 Europe Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 49 Europe Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 50 Europe Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 51 Europe Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 52 Europe Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 53 Europe Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 54 Europe Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 55 Europe Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 56 Europe Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 57 Europe Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 58 Europe Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 59 Europe Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 60 Europe Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 61 Europe Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 62 Europe Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 63 Europe Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 64 Europe Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 65 Europe Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 66 Europe Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 67 Asia Pacific Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
• Table 68 Asia Pacific Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 69 Asia Pacific Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 70 Asia Pacific Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 71 Asia Pacific Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 72 Asia Pacific Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 73 Asia Pacific Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 74 Asia Pacific Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 75 Asia Pacific Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 76 Asia Pacific Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 77 Asia Pacific Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 78 Asia Pacific Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 79 Asia Pacific Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 80 Asia Pacific Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 81 Asia Pacific Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 82 Asia Pacific Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 83 Asia Pacific Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 84 Asia Pacific Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 85 Asia Pacific Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 86 Asia Pacific Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 87 Asia Pacific Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 88 Asia Pacific Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 89 South America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
• Table 90 South America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 91 South America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 92 South America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 93 South America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 94 South America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 95 South America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 96 South America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 97 South America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 98 South America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 99 South America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 100 South America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 101 South America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 102 South America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 103 South America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 104 South America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 105 South America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 106 South America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 107 South America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 108 South America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 109 South America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 110 South America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 111 Middle East & Africa Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
• Table 112 Middle East & Africa Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
• Table 113 Middle East & Africa Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
• Table 114 Middle East & Africa Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
• Table 115 Middle East & Africa Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
• Table 116 Middle East & Africa Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
• Table 117 Middle East & Africa Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
• Table 118 Middle East & Africa Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
• Table 119 Middle East & Africa Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
• Table 120 Middle East & Africa Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
• Table 121 Middle East & Africa Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
• Table 122 Middle East & Africa Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
• Table 123 Middle East & Africa Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 124 Middle East & Africa Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
• Table 125 Middle East & Africa Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
• Table 126 Middle East & Africa Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
• Table 127 Middle East & Africa Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 128 Middle East & Africa Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
• Table 129 Middle East & Africa Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 130 Middle East & Africa Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 131 Middle East & Africa Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 132 Middle East & Africa Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Alpha Emitter Market is accounted for $678.4 million in 2023 and is expected to reach $1636.0 million by 2030 growing at a CAGR of 13.4% during the forecast period. An alpha emitter refers to a radioactive substance or isotope that undergoes alpha decay, emitting alpha particles during the process. Alpha particles consist of two protons and two neutrons, essentially equivalent to a helium-4 nucleus. This type of radioactive decay is characterized by the release of alpha particles from the atomic nucleus, resulting in the transformation of the original element into a new element with a lower atomic number. The use of alpha emitters has applications in various fields, including medicine, industry, and research.

According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging.

Market Dynamics:

Driver:

Rising awareness of alpha particle therapy

The market is experiencing a surge in awareness, particularly driven by the growing recognition of alpha particle therapy. As medical science advances, there is an increasing understanding of the therapeutic potential of alpha emitters in targeted cancer treatments. Alpha particle therapy delivers highly localized and potent radiation, enhancing its efficacy in treating certain types of cancers with minimal damage to surrounding healthy tissues. The rising awareness is likely to propel the demand for alpha emitters, driving further innovations and advancements in this field.

Restraint:

Short half-life of radiopharmaceuticals

The short half-life of radiopharmaceuticals in the market poses a challenge, limiting their effective application in medical and industrial settings. Rapid decay reduces the window of opportunity for administering treatments or conducting experiments, requiring efficient logistics and quick deployment. This constraint may impact the widespread adoption of alpha emitters, especially in scenarios where extended periods of radioactivity are crucial for desired outcomes, necessitating careful consideration of decay rates in planning and implementation.

Opportunity:

Advancements in nuclear medicine

Recent advancements in the market for nuclear medicine have focused on innovative targeted alpha-particle therapies. Alpha emitters exhibit high precision in cancer treatment by delivering localized radiation to tumour cells, minimizing damage to surrounding healthy tissues. These developments enhance the efficacy and safety of therapeutic interventions, marking significant progress in personalized medicine and improving outcomes for patients with certain types of cancer.

Threat:

Need for high capital investment

The market demands substantial capital investment due to the complex and specialized nature of alpha-emitting technologies. Establishing secure production facilities, ensuring compliance with stringent regulatory standards, and investing in advanced research and development for safe applications require significant financial resources. Additionally, the need for extensive safety measures and controlled environments adds to the overall high capital requirements, creating a barrier to entry for potential market participants.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by disrupting supply chains, delaying research and development projects, and impacting regulatory processes. The increased focus on healthcare during the pandemic has both positively and negatively affected the demand for alpha emitters used in medical applications. While the need for cancer treatments has grown, logistical challenges and prioritization of resources have presented obstacles. The overall market has experienced fluctuations due to the dynamic circumstances created by the global health crisis.

The bismuth segment is expected to be the largest during the forecast period

The bismuth segment is expected to be the largest during the forecast period. It is utilized in targeted alpha-particle radiotherapy for treating certain types of cancer. Its short half-life and ability to deliver high-energy alpha particles make it valuable for precise and effective cancer treatment. The increasing focus on innovative medical therapies has contributed to the growing demand for bismuth-213 and underscores its importance in advancing alpha emitter applications in the medical field.

The ovarian cancer segment is expected to have the highest CAGR during the forecast period

The ovarian cancer segment is expected to have the highest CAGR during the forecast period. This targeted approach minimizes damage to surrounding healthy tissue. However, regulatory approvals, safety considerations, and the need for further clinical evidence may impact their widespread adoption. The evolving landscape of ovarian cancer treatments and research will influence the role of alpha emitters in addressing this challenging disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to increasing applications in medical treatments, particularly in cancer therapy. Growing investments in nuclear power and research and development activities contribute to market expansion. Public perception and regulatory compliance remain pivotal factors influencing the growth of alpha emitters in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to increasing applications in medical treatments, research, and nuclear power generation. Rising prevalence of cancer fuels demand for targeted alpha-particle radiotherapy. The region's expanding healthcare sector and research activities contribute to the region's potential, but ongoing developments and adherence to safety protocols will play pivotal roles in shaping the trajectory of the market in this region.

Key players in the market

Some of the key players in Alpha Emitter market include Orano Group, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Novartis International AG, Bayer AG, NorthStar Medical Radioisotopes, Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd, Eckert & Ziegler, RadioMedix, Curium Pharma, Isotopen Technologien Munchen AG (ITM), Nordion Inc..

Key Developments:

In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S.

In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.

Types Covered:

• Lead
• Astatine
• Bismuth
• Radium
• Actinium
• Other Types

Sources Covered:

• Artificially Produced Sources
• Natural Sources

Applications Covered:

• Prostate Cancer
• Neuroendocrine Tumors
• Bone Metastases
• Ovarian Cancer
• Other Applications

End Users Covered:

• Specialty Clinics
• Diagnostic Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Researh Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Alpha Emitter Market, By Type

• 5.1 Introduction
• 5.2 Lead
• 5.3 Astatine
• 5.4 Bismuth
• 5.5 Radium
• 5.6 Actinium
• 5.7 Other Types

6 Global Alpha Emitter Market, By Source

• 6.1 Introduction
• 6.2 Artificially Produced Sources
• 6.3 Natural Sources

7 Global Alpha Emitter Market, By Application

• 7.1 Introduction
• 7.2 Prostate Cancer
• 7.3 Neuroendocrine Tumors
• 7.4 Bone Metastases
• 7.5 Ovarian Cancer
• 7.6 Other Applications

8 Global Alpha Emitter Market, By End User

• 8.1 Introduction
• 8.2 Specialty Clinics
• 8.3 Diagnostic Centers
• 8.4 Hospitals
• 8.5 Other End Users

9 Global Alpha Emitter Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Orano Group
• 11.2 Alpha Tau Medical Ltd
• 11.3 Actinium Pharmaceutical Inc.
• 11.4 Novartis International AG
• 11.5 Bayer AG
• 11.6 NorthStar Medical Radioisotopes
• 11.7 Fusion Pharmaceuticals Inc.
• 11.8 Telix Pharmaceuticals Ltd
• 11.9 Eckert & Ziegler
• 11.10 RadioMedix
• 11.11 Curium Pharma
• 11.12 Isotopen Technologien Munchen AG (ITM)
• 11.13 Nordion Inc.